Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
NCT ID: NCT04047901
Last Updated: 2019-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2016-11-07
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aerobic Exercise is Cardio-protective in Hemato-oncological Disease and New-onset Chemotherapy
NCT04476576
Exercise Response After Revalidation in Cancer Patients
NCT04461392
Effects of a Home-based Exercise Program on Functional Capacity and Quality of Life in Heart Failure Patients
NCT03615157
Cardiac Rehabilitation in Cardiomyopathies
NCT00966303
Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients
NCT01939795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary outcome: Muscle sympathetic nerve activity Secondary outcome: arterial baroreflex sensitivity, peripheral chemorreflex sensitivity, mecanic and muscuclar metaborreflex control, ubiquitin proteasome system activity.
Patients were divided into 2 groups-trained (n = 10) and non-trained (n = 10). Patients in the trained group will complete 16 weeks of aerobic training. Evaluation of cardiac function, functional capacity, quality of life and biochemical evaluation (troponin, hs-CRP and BNP). For muscle evaluation will be performed biopsy of the vastus lateralis muscle
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
A group of patients who will not be trained will be evaluated at baseline (pre) and after 16 weeks.
They are oriented to maintain lifestyle changes
No interventions assigned to this group
Training group
Patients will complete 16 weeks of training including 40 minutes of aerobic training, 15 minutes of resistive exercise and 5 minutes of relaxation.
exercise training
Patients undergo 16 weeks of physical training
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exercise training
Patients undergo 16 weeks of physical training
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Funcional Class I-III (NYHA)
* Ejection fraction \< o,55
* treated for heart failure
Exclusion Criteria
* Moderate to major valve disease
* Positive serology for Chagas
* Inability to perform physical exercises
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InCor Heart Institute
OTHER
Cancer Institute of Sao Paulo
UNKNOWN
Hospital Sirio-Libanes
OTHER
University of Sao Paulo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heart Institute of University of São Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Carlos Eduardo Negrao, PHD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SDC COP 002/15/002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.